Catalyst Wire Dossier Catalyst Wire Dossier

Effisayil

Spesolimab · Boehringer Ingelheim
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Effisayil, covering 2022-03-09 to 2022-03-09. Get the full timeline:

Most recent: Clinical Trial Update: Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis [Phase 2]

See pricing